Insulet Corporation logo

Insulet Corporation (PODD)

Market Closed
3 Mar, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
241. 84
-3.61
-1.47%
$
17.36B Market Cap
56.74 P/E Ratio
- Div Yield
903,589 Volume
2.99 Eps
$ 245.45
Previous Close
Day Range
236.51 243.1
Year Range
230.05 354.88
Want to track PODD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PODD earnings report is expected in 58 days (30 Apr 2026)
Here's Why Insulet (PODD) is a Strong Momentum Stock

Here's Why Insulet (PODD) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 9 months ago
Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 9 months ago
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

Insulet Corporation's NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500.

Marketbeat | 9 months ago
Outlier Money Flows Lift Insulet

Outlier Money Flows Lift Insulet

Big Money buying shares of Insulet Corporation (PODD).

Fxempire | 9 months ago
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks | 9 months ago
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks

S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks

Major U.S. equities indexes pulled back from their early gains Friday as investors wait for new developments on tariffs ahead of a weekend meeting between U.S. and Chinese officials.

Investopedia | 9 months ago
Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript

Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and CEO Ana Chadwick - EVP and CFO Eric Benjamin - Chief Product and Customer Experience Officer Conference Call Participants Travis Steve - Bank of America Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Patrick Wood - Morgan Stanley Marie Thibault - BTIG Michael Polark - Wolfe Research Matt O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Issie Kirby - Redburn Atlantic Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 9 months ago
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say

Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 9 months ago
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates

Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago.

Zacks | 9 months ago
Insulet beats quarterly profit estimates on insulin pump demand

Insulet beats quarterly profit estimates on insulin pump demand

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Reuters | 9 months ago
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Zacks | 10 months ago
Insulet Names New CEO, Expects to Top Revenue Projections

Insulet Names New CEO, Expects to Top Revenue Projections

Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.

Investopedia | 10 months ago
Loading...
Load More